Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-24 11:36 am Sale | 2025-11-21 | 13D | Tekla Life Sciences Investors HQL | Saba Capital Management L.P. | 2,274,356 7.880% | -312,296 (-12.07%) | Filing History |
| 2025-09-26 1:17 pm Sale | 2025-09-24 | 13D | Tekla Life Sciences Investors HQL | Saba Capital Management L.P. | 2,586,652 8.960% | -396,054 (-13.28%) | Filing History |
| 2025-09-03 4:58 pm Sale | 2025-08-29 | 13D | Tekla Life Sciences Investors HQL | Saba Capital Management L.P. | 2,982,706 10.330% | -205,699 (-6.45%) | Filing History |
| 2025-04-28 09:41 am Purchase | 2025-03-31 | 13G | Tekla Life Sciences Investors HQL | First Trust Portfolios L.P. | 1,827,112 6.330% | 1,249,420 (+216.28%) | Filing History |
| 2025-04-01 9:49 pm Purchase | 2025-03-31 | 13D | Tekla Life Sciences Investors HQL | Saba Capital Management L.P. | 3,188,405 11.360% | 3,188,405 (New Position) | Filing History |
| 2024-06-03 09:15 am Purchase | 2024-05-30 | 13D | Tekla Life Sciences Investors HQL | Saba Capital Management L.P. | 3,320,668 12.390% | 295,066 (+9.75%) | Filing History |
| 2024-04-29 10:52 am Purchase | 2024-04-25 | 13D | Tekla Life Sciences Investors HQL | Saba Capital Management L.P. | 3,025,602 11.290% | 412,829 (+15.80%) | Filing History |
| 2024-04-17 08:32 am Purchase | 2024-04-15 | 13D | Tekla Life Sciences Investors HQL | Saba Capital Management L.P. | 2,612,773 9.750% | 398,699 (+18.01%) | Filing History |
| 2024-02-07 07:55 am Purchase | 2024-02-05 | 13D | Tekla Life Sciences Investors HQL | Saba Capital Management L.P. | 2,214,074 8.260% | 457,547 (+26.05%) | Filing History |
| 2024-01-12 11:41 am Purchase | 2024-01-10 | 13D | Tekla Life Sciences Investors HQL | Saba Capital Management L.P. | 1,756,527 6.560% | 335,227 (+23.59%) | Filing History |
| 2023-12-29 07:54 am Purchase | 2023-12-20 | 13D | Tekla Life Sciences Investors HQL | Saba Capital Management L.P. | 1,421,300 5.310% | 1,421,300 (New Position) | Filing History |
| 2023-02-06 10:39 am Sale | 2022-12-31 | 13G | Tekla Life Sciences Investors HQL | First Trust Portfolios L.P. | 577,692 2.230% | -998,434 (-63.35%) | Filing History |
| 2022-01-21 11:09 am Sale | 2021-12-31 | 13G | Tekla Life Sciences Investors HQL | First Trust Portfolios L.P. | 1,576,126 6.330% | -144,560 (-8.40%) | Filing History |
| 2021-01-21 09:29 am Sale | 2020-12-31 | 13G | Tekla Life Sciences Investors HQL | First Trust Portfolios L.P. | 1,720,686 7.200% | -602,828 (-25.94%) | Filing History |